Name | Potential Indication | Status of Clinical Trial |
---|---|---|
ABT-288 | AD and schizophrenia | Phase II |
BF2.649 (Pitolisant) | Somnolence and EDS in narcolepsy and Parkinson's disease | Phase III |
Epilepsy | Phase II | |
Cognitive impairments | Phase II | |
GSK189254 | Sleep disorders | Phase I |
GSK239512 | AD and schizophrenia | Phases I and II |
JNJ-17216498 | Narcolepsy and ADHD | Phase II |
MK-0249 | Sleep disorders | Phase I |
MK-3134 | Sleep and cognitive disorders | Phase I |
PF-03654746 | Narcolepsy and cognitive disorders | Phase II |
AD, Alzheimer's disease; ADHD, attention-deficit hyperactivity disorder; EDS, excessive daytime sleepiness.